Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 11 | Rare Historical Photos

Moderna signs deal to make mRNA vaccines for Chinese market

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

Tribune News Service

A Long-Awaited Vaccine For Lyme Disease is Tantalizingly Close — Here's When It Could Be Available

Over the past twenty years, Lyme disease cases have continued to climb, and we are finally tantalizingly close to another vaccine.

Inverse

UK regulator sued for not investigating Covid vaccine ‘misinformation’

Case brought against General Medical Council for failure to look into claimed links to heart problems and deaths

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Health care providers are adding cloud tech, but need to dream bigger

Currently, the application of cloud in the health care space is choppy.

Fortune

Cancer vaccines are already a reality. Here's what you need to know about the cutting-edge technology that could usher in an era of personalized medicine

The concept may seem torn from the plot of some futuristic sci-fi movie, or from the pages of some decades-old utopian novel far ahead of its time. But such wonders of science exist today.

Fortune

Moderna Stock Rises After FDA Application For Updated Vaccine

Moderna's potential beyond COVID-19 is underappreciated, says analyst Eliana Merle, who upgraded the stock to Buy

Zenger

Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Should You Be Investing In?

Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, Moderna (MRNA) and BioNTech (BNTX), is a more favorable investment choice in the current uncertain economic climate. Keep reading to find out.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

mRNA Vaccines Could Revolutionize Cancer Treatment

Here’s a look at the status of mRNA technology's application in cancer and when it might reach patients.

Inverse

Devastating virus few parents know about hits three babies a day

World-first vaccine trials have now begun in a bid to protect children from CMV

Wales Online

Scottish Mortgage sees share price fall by a third

Net asset value also fell by more than 17% during a year that has been 'painful for shareholders'

Insider UK

These Next-Generation Vaccines Could Upend Cancer Treatment As We Know It

New high-tech vaccines could help combat common yet deadly conditions like cancer and heart disease.

Inverse

The Vaccine Problem

To better weather future pandemics, the way countries procure vaccines needs to change radically

The Walrus

mRNA technology beat COVID-19, can it do the same for pancreatic cancer?

Half the pancreatic cancer patients in a new clinical trial were alive and cancer free after 18 months. Most usually die within three months.

The New Daily

FDA approves first vaccine for respiratory syncytial virus

The FDA has approved the first vaccine for respiratory syncytial virus (RSV).

The Hindu

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Moderna Stock Pops on Surprise Earnings Beat

An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

The Texas Tribune

Attorney General Ken Paxton to investigate COVID-19 vaccine makers

Long an opponent of vaccine and mask mandates, the Republican said pharmaceutical companies may have misrepresented data. Pfizer strongly disagrees.

The Week

Lyme disease: vaccine could halt rise of tick-borne disease

A vaccine for Lyme disease could be available soon, according to reports.

Fortune

Moderna's CEO shares what it was like to leap from pre-revenue startup to Fortune 500 company

The COVID-19 vaccine turned Moderna into a household name. What's next for the company?

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Extra spring COVID booster cleared for certain Americans

Certain Americans at high risk from COVID-19 can get an extra vaccine booster this spring

Evening Standard

Autumn Covid booster 2023: Who is eligible for another jab?

If invited, you will receive a booster dose of a Covid-19 vaccine made by Pfizer, Moderna, or Sanofi

The Week

Sanofi: the new protein-based Covid vaccine to be used in the UK

The University of Edinburgh’s Neil Mabbott on the vaccine technology being used for Covid booster jabs from this month.

Tribune News Service

Study: Vaccine helps drug keep melanoma patients cancer-free

Adding a personalized cancer vaccine to the blockbuster drug Keytruda kept more melanoma patients in remission than the immune therapy alone, co-developers Moderna Inc. and Merck & Co. said in their first detailed presentation of a key study.

Wales Online

Everything we know about new Sanofi Covid vaccine now being used in UK

The vaccine being used in the Spring booster campaign works in a different way to previous jabs

The Conversation

Sanofi vaccine: what to know about this protein-based COVID booster being offered in the UK

In the UK a spring booster campaign has recently begun, offering an additional vaccine to people at highest risk from COVID. Between April and June 2023 people aged over 75, residents in care homes and children and adults aged five and up with weakened immune systems will be invited to…

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.